Eric Dube, Travere Therapeutics CEO

Sev­er­al months af­ter re­brand­ing, an old Mar­tin Shkre­li com­pa­ny touts promis­ing piv­otal da­ta in a rare kid­ney dis­or­der

If all goes well at the FDA, Cal­lid­i­tas could cross the fin­ish line with its in­flam­ma­to­ry kid­ney dis­ease treat­ment Ne­fe­con next month. But Tra­vere Ther­a­peu­tics isn’t far be­hind — and on Mon­day, the for­mer Mar­tin Shkre­li com­pa­ny un­veiled some promis­ing piv­otal da­ta that may give Cal­lid­i­tas a run for its mon­ey.

Af­ter 36 weeks of treat­ment with Tra­vere’s sparsen­tan, pa­tients with a rare con­di­tion called IgA nephropa­thy saw a mean re­duc­tion in pro­tein­uria (ex­ces­sive pro­tein in the urine) of 49.8% from base­line, the com­pa­ny said. That com­pares to a mean re­duc­tion of 15.1% in a group of pa­tients who took Avapro, a cur­rent stan­dard of care (p<0.0001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.